Skip to main content
Premium Trial:

Request an Annual Quote

LumiGene Inks Reverse Acquisition Pact with Pole Perfect; Dances into Public Market

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – LumiGene today announced it has signed a letter of intent to be acquired by dance studio Pole Perfect Studios in a reverse acquisition that will take LumiGene public.

Upon completion of the deal, LumiGene will become the primary focus of the combined company.

Terms of the deal were not disclosed.

LumiGene, based in Mississauga, Ontario, develops point-of-care diagnostics. Its main technology is the PosiChek Diagnostic System, an automated nucleic acid testing system for preparing and amplifying nucleic acid for the detection of disease-causing pathogens within one hour.

Pole Perfect, based in Longwood, Fla., operates a dance studio "that offers a full line of services not traditionally found at health and fitness centers that will cater to both genders," according to a document filed with the US Securities and Exchange Commission. The company's stock is traded on the over-the-counter bulletin board under the ticker symbol PPFT. Its last trade was on July 29 at $.14.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.